Joel Dillon Crandall

Array ( [id] => 17865426 [patent_doc_number] => 20220288161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => TSG6 POLYPEPTIDE FRAGMENT FOR DRY EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/597802 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16360984 [patent_doc_number] => 20200317735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/904920 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20413013 [patent_doc_number] => 12496275 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Drug delivery methods and compositions [patent_app_type] => utility [patent_app_number] => 17/618389 [patent_app_country] => US [patent_app_date] => 2020-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 60 [patent_no_of_words] => 26213 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310867 [patent_doc_number] => 20200289605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => COMPOSITION FOR IMPROVING OR PREVENTING NONALCOHOLIC FATTY LIVER [patent_app_type] => utility [patent_app_number] => 16/889367 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482343 [patent_doc_number] => 20200375943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => CYTOCIDAL METHOD OF CANCER CELLS SELECTIVELY IN HUMAN PATIENTS CLINICALLY BY DEPLETION OF L-ASCORBIC ACID, PRIMARILY, WITH ITS SUPPLEMENTATION ALTERNATELY AUGMENTING ITS CYTOCIDAL EFFECT [patent_app_type] => utility [patent_app_number] => 16/886749 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16886749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828456 [patent_doc_number] => 20220265760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/614312 [patent_app_country] => US [patent_app_date] => 2020-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512923 [patent_doc_number] => 20200392181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => PEPTIDE COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/882656 [patent_app_country] => US [patent_app_date] => 2020-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437076 [patent_doc_number] => 20200354402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => PEPTIDE COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/882660 [patent_app_country] => US [patent_app_date] => 2020-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749633 [patent_doc_number] => 20220227837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => IL-2 COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/609638 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792050 [patent_doc_number] => 20220251141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => IMMUNOMODULATORS [patent_app_type] => utility [patent_app_number] => 17/612915 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 522 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17612915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297780 [patent_doc_number] => 20200283503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => CD44V6-DERIVED CYCLIC PEPTIDES FOR TREATING CANCERS AND ANGIOGENESIS RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 16/878872 [patent_app_country] => US [patent_app_date] => 2020-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 257 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16878872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719089 [patent_doc_number] => 20220211808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE [patent_app_type] => utility [patent_app_number] => 17/595390 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685912 [patent_doc_number] => 20220193204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR [patent_app_type] => utility [patent_app_number] => 17/595245 [patent_app_country] => US [patent_app_date] => 2020-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734715 [patent_doc_number] => 20220220174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => BNIP3 PEPTIDES FOR TREATMENT OF REPERFUSION INJURY [patent_app_type] => utility [patent_app_number] => 17/608655 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719138 [patent_doc_number] => 20220211857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => POLYPEPTIDE DERIVATIVE AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 17/610606 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8102 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858544 [patent_doc_number] => 11439682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Treating IgE-mediated allergic diseases [patent_app_type] => utility [patent_app_number] => 16/862512 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24773 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 215 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17968253 [patent_doc_number] => 11485767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Multivalent PD-L1 binding compounds for treating cancer [patent_app_type] => utility [patent_app_number] => 16/860637 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 18908 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17028562 [patent_doc_number] => 11090360 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Applications of mussel adhesive protein product in treatment and prevention of diseases related to melanin [patent_app_type] => utility [patent_app_number] => 16/859458 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7553 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221388 [patent_doc_number] => 20200246504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES [patent_app_type] => utility [patent_app_number] => 16/856031 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911395 [patent_doc_number] => 20220313790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => HUMAN ALBUMIN-CONTAINING MEDICAL PRODUCT AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 17/642239 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642239 [rel_patent_id] =>[rel_patent_doc_number] =>)